We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant
ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 …

The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown
remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer …

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the
expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was …

Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified
as driver mutations in non‐small‐cell lung cancer, inflammatory myofibroblastic tumors, and …

EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell
lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (p21p23) …

Since 2011, with the approval of crizotinib and subsequent approval of four additional
targeted therapies, anaplastic lymphoma kinase (ALK) inhibitors have become important …

Introduction: Anaplastic lymphoma kinase (ALK) and ROS1 rearrangements define
important molecular subgroups of advanced non-small cell lung cancer (NSCLC). The …

Anaplastic lymphoma kinase (ALK) can be driven to oncogenic activity by different types of
mutational events such as point‐mutations, for example F1174L in neuroblastoma, and …

The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring
chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by …

Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …